Juvaris gets infusion for infectious disease vaccines
Juvaris BioTherapeutics, a Burlingame, Calif.-based developer of vaccines to treat infectious diseases, announced that it raised financing toward its targeted $25 million second round of funding from SV Life Sciences and Kleiner Perkins Caufield & Byers. The company wouldn’t put a finer point on the amount, mostly because it is open to further investments in the round.
The money will give Juvaris a two-year runway to improve the immune responses caused by its vaccines. Right now,… Continue Reading
Life sciences briefing: Friday, Nov. 2, 2007
Featured companies: Ascent Therapeutics, Bas Medical, Bikam Pharmaceuticals, Fundamental Applied Biology, Juvaris BioTherapeutics, Medavante, Trivitron, Vapotherm
UPDATED: Expanded items on Bas Medical and Juvaris.
Bas Medical raises $20M for heart-failure drug — San Mateo, Calif.-based Bas Medical, a biotech developing drugs based on a hormone called relaxin, raised $20 million in a third funding round, VentureWire reports (subscription required). Investors included Domain Associates, Kleiner Perkins Caufield & Byers and Sears Capital Management.
Relaxin is a natural peptide hormone whose levels… Continue Reading
Influenza and pneumonia co., Juvaris, raises $6M from Kleiner
Juvaris BioTherapeutics, a Pleasanton, Calif. company developing vaccine products for influenza and pneumonia, said it has raised the first $6 million half of its first round of funding .
The financing comes from Kleiner Perkins, the well-known venture firm that has focused its investments in the pandemic area with its “Pandemic & Biodefense Fund.”
Juvaris said it will close the second part of its round in 120 days, and that the total raised will be $12… Continue Reading
Cancer vaccine developer Juvaris raises $7.53M, led by Kleiner Perkins
Juvaris BioTherapeutics, a Pleasanton, Calif. developer of vaccines for cancer and infectious diseases, has raised $7.53 million in a first round of funding led by Kleiner Perkins Caufield & Byers, according to a regulatory filing cited by PE Wire.
Tom Monath of KPCB will serve on the Juvaris board of directors. Juvaris had said on its website that it was seeking “$10 million to commence full-scale operations.” Company CEO Martin Cleary declined to comment.